Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2020

Gibert Joan, Clavé Sergi, Hardy-Werbin Max, Taus Álvaro, Rocha Pedro, Longarón Raquel, Piquer Gabriel, Chaib Imane, Carcereny Enric, Morán Teresa, Salido Marta, Dalmases Alba, Bellosillo Beatriz, Arriola Edurne

Abstract excerpt

OBJECTIVES: KRAS mutations are one of the most prevalent alterations in non-small cell lung cancer. However, patients with this driver alteration present heterogeneous clinical outcomes. In this study, we have explored the potential clinical impact of coexisting alterations in this subset of patients. MATERIALS AND METHODS: Samples from a cohort of 69 lung adenocarcinoma patients homogenously treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Platinum

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Source

Identifiers

PMID: 31862576
DOI: 10.1016/j.lungcan.2019.12.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.PMID 31862576Read ↗

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients.Semantic proximity Read ↗

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysSemantic proximity Read ↗

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.Semantic proximity Read ↗

Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression.Semantic proximity Read ↗

Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A One Institution Retrospective AnalysisSemantic proximity Read ↗

Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.Semantic proximity Read ↗

Next-Generation Sequencing Reveals Distinct Molecular Patterns in Lung Cancer: KRAS-Driven Adenocarcinoma and Limited Comutations in EGFR-Mutated TumorsSemantic proximity Read ↗

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery.Semantic proximity Read ↗

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.